Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor in advanced pancreatic, ovarian and colorectal cancer
NCT03277209Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jul 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in pancreatic adenocarcinoma (PDAC), High-Grade Serous Ovarian Carcinoma (HGSOC) and colorectal adenocarcinoma, sponsored by Weill Cornell Medicine. Primary endpoint: Causality of adverse events (AEs) and serious adverse events (SAEs) at Day 56. Started Jul 2017; status: terminated.
02
Drugs
plerixafor
03
Conditions
pancreatic adenocarcinoma (PDAC)High-Grade Serous Ovarian Carcinoma (HGSOC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT03277209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277209.